Systematic review of interventions to repair ascending aortic pseudoaneurysms.

BACKGROUND: The safety and efficacy of endovascular therapies for ascending aortic pseudoaneurysms (AAPs) are still controversial. METHODS: We report an endovascular correction of an AAP in a high-risk surgical patient and present the results of a literature review focusing on AAP treatment strategies. A multilingual search of AAP therapy was performed with limiting dates of January 1980 to May 2014. The studies were classified by intervention. RESULTS: A 79-year-old male with a 9 × 10 × 7 cm AAP in the anterior mediastinum was considered too high risk for surgery. An endovascular closure with a 12 mm Amplatzer septal occluder device (St. Jude Medical) was performed, and computed tomography angiography at 3-month follow-up exhibited a thrombosed AAP with minimal residual shunt. In our literature search, we identified 355 cases of AAPs, mostly case reports (91.5%) and a few patient series (8.5%). Surgical correction accounted for 73.8% of the cases, 5% of the patients were conservatively treated or considered too critically ill for any intervention, and 21.2% were treated with endovascular techniques. The most commonly reported endovascular techniques were stent grafts (9.8%) and septal occluder devices (9.8%). CONCLUSION: Although endovascular closure of AAPs with off-label devices is a reliable option for controlling the expansion and symptoms in high-risk surgical patients, solid data on survival are lacking. Efforts to promote discussion within the heart team to expand the application of endovascular techniques can provide groundbreaking evidence to support the use of endovascular techniques as guideline therapy when facing these complicated cases.

Cardiovascular adaptation and cardiac disease in the elite athlete.

Cardiovascular diseases are uncommon among trained athletes. Their occurrences mostly depend on the individual's age and fitness levels. Adequate understanding of the cardiovascular adaptations undergone by the competitive athletes' heart is of paramount importance in order to differentiate them from serious cardiovascular conditions. Diagnosing these abnormalities early may prevent rare but devastating potential complications associated with athletic activities and defines appropriate activity restrictions to minimize the risk of sudden cardiac death. This article will review concerns related to competitive athlete's cardiovascular adaptations and diseases, in light of specific recommendations presented in the 36th Bethesda Conference guidelines.

Sudden cardiac death in the elite athlete.

Sudden cardiac death (SCD) is a long -recognized disease that occurs rarely in trained athletes. Most affected athletes have no symptoms before death. Many attempts have been made to detect those at risk for SCD before athletic participation. However, its overall clinical advantages remain questionable in medical literature. This article will review cardiogenic and non-cardiogenic causes of SCD as well as discuss how this entity affects those athletes older than 35 years.

Prevalence of anemia in a Hispanic population with decompensated congestive heart failure.

UNLABELLED: Anemia in patients with heart failure (HF is a frequent event, commonly associated with worse prognosis. Despite the high incidence and adverse outcomes associated with anemia no studies have been conducted amongst Hispanics with HF. OBJECTIVE: The study aims to determine the prevalence, predictors and outcomes of anemia in Hispanics admitted to Veteran Affairs Caribbean Healthcare System with diagnosis of Decompensated Congestive Heart Failure (D-CHF). METHODS: Retrospective review of 617 patient medical charts that had been previously discharged with a diagnosis of HF as per International Classification of Diseases-9 code. The clinical, demographic, laboratory and echocardiographic data was assessed for a total of 148 male patient electronic medical records that met the study inclusion criteria. The re-hospitalization and mortality rates were determined from the admission date until April 2010. RESULTS: The burden of anemia with HF is substantial, with anemia present in 68.2% of patients. Anemia was associated with hypoalbuminemia, higher New York Heart Association classification, elevated pro-BNP level at discharge, renal insufficiency and diastolic dysfunction, all of which demonstrated statistical significance. Anemia had 2.18 and 2.95 times likelihood of any-cause mortality (p = 0.003) and cardiovascular deaths (p = 0.02) when compared with HF patients without anemia. CONCLUSIONS: Anemia is a very frequent and serious finding in patients with D-CHF. The study reveals a higher prevalence of anemia in HF patients among Hispanics in comparison with formerly reported studies covering non-Hispanic populations.